Oramed Pharmaceuticals Inc. (ORMP) Stock Price & Analysis
Oramed Pharmaceuticals Inc. (ORMP) closed at USD 4.18 on Thursday, October 15, 2026, up 0.97% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.14; the Oct 15, 2026 session ranged USD 4.15–4.28 on volume of 128,183 shares. Market capitalization is $173.88M, with a 52-week range of USD 2.09–5.47 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ORMP.md
Key facts (ORMP)
- Analysts: None (1 analysts), mean target USD 7 (range 7–7).
- Total return with dividends: 1Y +97.5% vs S&P 500 +18.1%; 5Y -79.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD 0.43, revenue estimate $0K.
Analysts (ORMP)
Consensus None, 1 analysts; mean target USD 7 (low 7, high 7).
Total return (dividends reinvested) (ORMP)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +97.5% | -79.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +98.0% | -27.2% |
| Volatility (annualized) | 52.8% | 97.8% |
| Max drawdown | -23.9% (May 2026→Jun 2026) | -93.8% (Nov 2021→Oct 2023) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 4.18 |
|---|---|
| Change | ▲ 0.97% (up) |
| Previous Close | USD 4.14 |
| Open | USD 4.18 |
| Day Range | USD 4.15 – 4.28 |
| 52-Week Range | USD 2.09 – 5.47 |
| Volume | 128,183 shares |
| Market Cap | $173.88M |
| Exchange | NCM |
Technical Analysis (ORMP)
Nexqual's technical model rates ORMP "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.86 (neutral) |
| vs SMA50 | Below (USD 4.64) |
| MACD | -0.14 (negative) |
Analyst Ratings (ORMP)
Wall Street analysts rate ORMP "None" based on 1 analysts, with a mean price target of USD 7 (range USD 7–7), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 7 |
| High Target | USD 7 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 0 / 0 / 0 |
Earnings (ORMP)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.84 vs est 0.43 ▲ beat |
| 2025-12-31 | USD 0.25 vs est 0 ▲ beat |
| 2025-09-30 | USD 1.13 vs est -0.04 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (ORMP)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | +74.24% |
| Debt / Equity | 0 |
| Current Ratio | 4.98 |
| Total Cash | $50.61M |
| Total Debt | $733,000 |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (ORMP)
Nexqual rates Oramed Pharmaceuticals Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $51M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M (TTM) |
| Efficiency | Strong — ROE 74%, ROA -3.4% |
Ownership (ORMP)
| Insider Ownership | +21.27% |
|---|---|
| Institutional Ownership | +45.13% |
| Shares Outstanding | 41.60M |
| Float | 29.83M |
| Short % of Float | +4.16% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (ORMP)
Oramed Pharmaceuticals Inc. is led by Nadav Kidron (age 51), President, CEO & Executive Chairman, per Nexqual as of October 16, 2026 at 05:19 UTC.
| President, CEO & Executive Chairman | Nadav Kidron (age 51) |
|---|---|
| Chief Operating & Business Officer | Joshua Hexter (age 55) |
| Chief Scientific Officer & Director | Miriam Kidron (age 85) |
| CFO, Treasurer & Secretary | Avraham Gabay (age 40) |
Major Backers & Investors (ORMP)
Notable institutional backers of Oramed Pharmaceuticals Inc. include Mercer Global Advisors, Inc./ADV, Aquamarine Financial (cayman) Ltd, Gem Investment Advisors, LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Mercer Global Advisors, Inc./ADV | 9.16% |
| Aquamarine Financial (cayman) Ltd | 6.04% |
| Gem Investment Advisors, LLC | 4.81% |
| Murchinson Ltd. | 3.1% |
| BML Capital Management, LLC | 2.08% |
| Boothbay Fund Management, LLC | 1.39% |
| Fidelity | 1.03% |
| Goldman Sachs | 0.75% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.41% |
| Geode Capital | 1.2% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt